Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lennon, V. A.
Right arrow Articles by Griesmann, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lennon, V. A.
Right arrow Articles by Griesmann, G. E.
NEUROLOGY 1989;39:1069
© 1989 American Academy of Neurology

Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis

Vanda A. Lennon, MD, PhD and Guy E. Griesmann, MS

Departments of Immunology and Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN.

We investigated specificities of acetylcholine receptor (AChR) antibodies in 100 seropositive patients with myasthenia gravis (MG). Antibodies in 74 of these sera were inhibited by more than 50% from binding to human muscle AChR by a rat monoclonal antibody (mAb) of "main immunogenic region" (MIR) specificity. The mAb inhibition was not explainable by epitope competition because (1) the mAb was reactive with both Torpedo and human AChR, but antibodies in 85 of the MG sera did not bind to Torpedo AChR, and (2) the mAb blocked binding of rat anti-peptide antibodies to an a subunit region of the human AChR unrelated antigenically to the designated MIR region. Individual patients' sera had evidence of extensive antibody heterogeneity and revealed interspecies polymorphisms in AChR antigenicity, near and remote from the neurotransmitter-binding region. The data challenge the concept that a MIR of the AChR is the principal stimulus for antibody production in MG, and emphasize a potential pitfall in assuming seronegativity in MG on the basis of a single assay system.

Address correspondence and reprint requests to Dr. Lennon, Neuroimmunology Laboratory, Rm. 828, Guggenheim Bldg., Mayo Clinic, Rochester, MN 55905.

Supported by Grant NS 15057 from the National Institutes of Health, and by the William K. Warren Foundation.

Received December 15, 1988. Accepted for publication in final form February 22, 1989.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
S. Vernino, L. G. Ermilov, L. Sha, J. H. Szurszewski, P. A. Low, and V. A. Lennon
Passive Transfer of Autoimmune Autonomic Neuropathy to Mice
J. Neurosci., August 11, 2004; 24(32): 7037 - 7042.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by AAN Enterprises, Inc.